Add to ORKGMirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studie
Purpose: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-inclassnovel β3 r...
No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in ...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Introduction To examine pooled efficacy data from three, large phase III studies comparing mirabegro...
Contains fulltext : 214085.pdf (Publisher’s version ) (Open Access
INTRODUCTION: Mirabegron is a selective \u3b23-adrenergic receptor agonist recently developed for th...
Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative ...
Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Anti...
Objective: This review aimed to evaluate the efficacy and safety of mirabegron as monotherapy and it...
Purpose We performed a meta-analysis to evaluate the efficacy and safety of mirabegron add-on therap...
AbstractObjectiveMirabegron, a β3-adrenoceptor agonist, has been shown to be effective and safe in t...
Aleksiewicz Tomasz, Leis Kamil, Świerczyński Wojciech, Miętkiewicz Kacper, Litwin Katarzyna, Gałązka...
AbstractMirabegron, the first β3-adrenoceptor agonist introduced for use in clinical practice, diffe...
Mirabegron is a novel, once-daily, orally active, first-in-class, potent β 3 -adrenoceptor agonist r...
Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinenc...
Purpose: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-inclassnovel β3 r...
No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in ...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Introduction To examine pooled efficacy data from three, large phase III studies comparing mirabegro...
Contains fulltext : 214085.pdf (Publisher’s version ) (Open Access
INTRODUCTION: Mirabegron is a selective \u3b23-adrenergic receptor agonist recently developed for th...
Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative ...
Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Anti...
Objective: This review aimed to evaluate the efficacy and safety of mirabegron as monotherapy and it...
Purpose We performed a meta-analysis to evaluate the efficacy and safety of mirabegron add-on therap...
AbstractObjectiveMirabegron, a β3-adrenoceptor agonist, has been shown to be effective and safe in t...
Aleksiewicz Tomasz, Leis Kamil, Świerczyński Wojciech, Miętkiewicz Kacper, Litwin Katarzyna, Gałązka...
AbstractMirabegron, the first β3-adrenoceptor agonist introduced for use in clinical practice, diffe...
Mirabegron is a novel, once-daily, orally active, first-in-class, potent β 3 -adrenoceptor agonist r...
Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinenc...
Purpose: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-inclassnovel β3 r...
No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in ...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...